Regulus Therapeutics Total Liabilities

Regulus Therapeutics (RGLS) currently reports a total liabilities of $5.8M as of March 2025. That compares with $6.6M in the prior-year period — down 11.5% year over year. Use the charts on this page to explore Regulus Therapeutics's total liabilities history and peer comparisons.

Regulus Therapeutics's total liabilities decreased from $6.6M to $5.8M — a 11.5% year-over-year decrease (period ending March 2025). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Regulus Therapeutics reported $5.8M in total liabilities as of March 2025. That compares with $6.6M in the prior-year period — down 11.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current total liabilities of $5.8M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Regulus Therapeutics, and consider following RGLS for alerts when major investors trade the stock.

Regulus Therapeutics is classified in the Healthcare sector. On total liabilities, it currently shows $5.8M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing RGLS with unrelated industries.